Cargando…

Rational Design of Antirheumatic Prodrugs Specific for Sites of Inflammation

OBJECTIVE: Biologic drugs, such as the anti–tumor necrosis factor (anti‐TNF) antibody adalimumab, have represented a breakthrough in the treatment of rheumatoid arthritis. Yet, concerns remain over their lack of efficacy in a sizable proportion of patients and their potential for systemic side effec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Onuoha, Shimobi C., Ferrari, Mathieu, Sblattero, Daniele, Pitzalis, Costantino
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2015
Materias:	Rheumatoid Arthritis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4832285/ https://www.ncbi.nlm.nih.gov/pubmed/26097196 http://dx.doi.org/10.1002/art.39232

Ejemplares similares

Subcutaneous Tocilizumab Versus Placebo in Combination With Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis
por: Kivitz, Alan, et al.
Publicado: (2014)

Patients’ Attitudes and Experiences of Disease‐Modifying Antirheumatic Drugs in Rheumatoid Arthritis and Spondyloarthritis: A Qualitative Synthesis
por: Kelly, Ayano, et al.
Publicado: (2018)

Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease‐Modifying Antirheumatic Drug Treatment
por: Fleischmann, Roy, et al.
Publicado: (2017)

In vitro evaluation of disease-modifying antirheumatic drugs against rheumatoid arthritis associated pathogens of the oral microflora
por: Kussmann, Manuel, et al.
Publicado: (2021)

Tapering glucocorticoids and risk of flare in rheumatoid arthritis on biological disease-modifying antirheumatic drugs (bDMARDs)
por: Adami, Giovanni, et al.
Publicado: (2023)

Effect of disease duration and prior disease-modifying antirheumatic drug use on treatment outcomes in patients with rheumatoid arthritis
por: Aletaha, Daniel, et al.
Publicado: (2019)

Subsequent Cardiovascular Events Among Patients With Rheumatoid Arthritis, Psoriatic Arthritis, or Psoriasis: Patterns of Disease‐Modifying Antirheumatic Drug Treatment
por: Sparks, Jeffrey A., et al.
Publicado: (2019)

Cardiovascular effects of biological versus conventional synthetic disease-modifying antirheumatic drug therapy in treatment-naïve, early rheumatoid arthritis
por: Plein, Sven, et al.
Publicado: (2020)

Sarilumab and Nonbiologic Disease‐Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors
por: Fleischmann, Roy, et al.
Publicado: (2017)

Safety of biological and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis as used in clinical practice: results from the ARTIS programme
por: Frisell, Thomas, et al.
Publicado: (2023)

Effects of baricitinib on radiographic progression of structural joint damage at 1 year in patients with rheumatoid arthritis and an inadequate response to conventional synthetic disease-modifying antirheumatic drugs
por: van der Heijde, Desirée, et al.
Publicado: (2018)

Register-based observational study of associations between inflammatory remission, formal treatment targets and the use of disease-modifying antirheumatic drugs among patients with early rheumatoid arthritis
por: Lindqvist, Joakim, et al.
Publicado: (2023)

Comparative cardiovascular safety with janus kinase inhibitors and biological disease-modifying antirheumatic drugs as used in clinical practice: an observational cohort study from Sweden in patients with rheumatoid arthritis
por: Bower, Hannah, et al.
Publicado: (2023)

Risk of major adverse cardiovascular events in patients with rheumatoid arthritis treated with conventional synthetic, biologic and targeted synthetic disease-modifying antirheumatic drugs: observational data from the German RABBIT register
por: Meissner, Yvette, et al.
Publicado: (2023)

Evaluation of the efficacy and safety of sarilumab combination therapy in patients with rheumatoid arthritis with inadequate response to conventional disease-modifying antirheumatic drugs or tumour necrosis factor α inhibitors: systematic literature review and network meta-analyses
por: Choy, Ernest, et al.
Publicado: (2019)

Investigation of genetically regulated gene expression and response to treatment in rheumatoid arthritis highlights an association between IL18RAP expression and treatment response
por: Cherlin, Svetlana, et al.
Publicado: (2020)

Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study): a randomised, double-blind, placebo-controlled phase 3 trial
por: Takeuchi, Tsutomu, et al.
Publicado: (2019)

Comparative effectiveness of improvement in pain and physical function for baricitinib versus adalimumab, tocilizumab and tofacitinib monotherapies in rheumatoid arthritis patients who are naïve to treatment with biologic or conventional synthetic disease-modifying antirheumatic drugs: a matching-adjusted indirect comparison
por: Fautrel, B, et al.
Publicado: (2020)

Role of synovial fibroblast subsets across synovial pathotypes in rheumatoid arthritis: a deconvolution analysis
por: Micheroli, Raphael, et al.
Publicado: (2022)

Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients
por: Humby, Frances, et al.
Publicado: (2019)

The Impact of Inflammation on Metabolomic Profiles in Patients With Arthritis
por: Young, Stephen P, et al.
Publicado: (2013)

Rheumatoid Arthritis Naive T Cells Share Hypermethylation Sites With Synoviocytes
por: Rhead, Brooke, et al.
Publicado: (2017)

The value of MRI for detecting subclinical joint inflammation in clinically suspect arthralgia
por: Boeren, Anna M. P., et al.
Publicado: (2022)

B Cell Synovitis and Clinical Phenotypes in Rheumatoid Arthritis: Relationship to Disease Stages and Drug Exposure
por: Rivellese, F., et al.
Publicado: (2020)

Association of response to TNF inhibitors in rheumatoid arthritis with quantitative trait loci for CD40 and CD39
por: Spiliopoulou, Athina, et al.
Publicado: (2019)

Association Between Genetic Variation in FOXO3 and Reductions in Inflammation and Disease Activity in Inflammatory Polyarthritis
por: Viatte, Sebastien, et al.
Publicado: (2016)

What is the prevalence of MRI-detected inflammation and erosions in small joints in the general population? A collation and analysis of published data
por: Mangnus, Lukas, et al.
Publicado: (2015)

Baseline Objective Inflammation by Magnetic Resonance Imaging as a Predictor of Therapeutic Benefit in Early Rheumatoid Arthritis With Poor Prognosis
por: Ahmad, Harris A., et al.
Publicado: (2020)

Frequency of joint inflammation is associated with local joint damage progression in rheumatoid arthritis despite long-term targeted treatment
por: Heckert, Sascha L, et al.
Publicado: (2023)

Value of imaging detected joint inflammation in explaining fatigue in RA at diagnosis and during the disease course: a large MRI study
por: Matthijssen, X M E, et al.
Publicado: (2021)

Stage-specific roles of microbial dysbiosis and metabolic disorders in rheumatoid arthritis
por: Cheng, Mingyue, et al.
Publicado: (2022)

Prospective, simultaneous assessment of joint and vascular inflammation by PET/CT in tofacitinib-treated patients with rheumatoid arthritis: associations with vascular and bone status
por: Hamar, Attila, et al.
Publicado: (2021)

Inflammation and biologic therapy in patients with rheumatoid arthritis achieving versus not achieving ACR/EULAR Boolean remission in a treat-to-target study
por: Paulshus Sundlisæter, Nina, et al.
Publicado: (2022)

Relative importance of inflammation and cardiorespiratory fitness for all-cause mortality risk in persons with rheumatoid arthritis: the population-based Trøndelag Health Study
por: Videm, Vibeke, et al.
Publicado: (2023)

Intermetatarsal Bursitis, a Novel Feature of Juxtaarticular Inflammation in Early Rheumatoid Arthritis Related to Clinical Signs: Results of a Longitudinal Magnetic Resonance Imaging Study
por: van Dijk, Bastiaan T., et al.
Publicado: (2022)

Moderate use of alcohol is associated with lower levels of C reactive protein but not with less severe joint inflammation: a cross-sectional study in early RA and healthy volunteers
por: Mangnus, Lukas, et al.
Publicado: (2018)

The Interleukin‐1 Receptor–Associated Kinase 4 Inhibitor PF‐06650833 Blocks Inflammation in Preclinical Models of Rheumatic Disease and in Humans Enrolled in a Randomized Clinical Trial
por: Winkler, Aaron, et al.
Publicado: (2021)

Repair of joint damage in patients with rheumatoid arthritis does not relate to previous suppression of inflammation: a subanalysis after 8 years treat-to-target in the BeSt-trial
por: van der Pol, Joy Ardjuna, et al.
Publicado: (2023)

Allele-specific protein binding within the CD40 locus in human synovial fibroblasts and immune cells
por: Moser, Larissa, et al.
Publicado: (2023)

HLA–DRB1 Amino Acid Positions 11/13, 71, and 74 Are Associated With Inflammation Level, Disease Activity, and the Health Assessment Questionnaire Score in Patients With Inflammatory Polyarthritis
por: Ling, Stephanie F., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_41ikq1ve4k3dmof52jvcf5rbmk